



BIONEER

Innovation • Value • Discovery

***“Making a Healthier Future for
Humanity with Genomic Technology”***

SEPT. 23, 2021



Disclaimer

These presentation materials have been prepared by Bioneer Corporation ("Bioneer" or the "Company"), solely for the use at this presentation and have not been independently verified.

No representations or warranties, express or implied, are made as to, and no reliance should be placed on, the accuracy, fairness or completeness of the information presented or contained in these materials. Neither the Company nor any of its affiliates, advisers or representatives accepts any responsibility whatsoever for any loss or damage arising from any information presented or contained in these materials. The information presented or contained in these materials is current as of the date hereof and is subject to change without notice and its accuracy is not guaranteed. Neither the Company nor any of its affiliates, advisers or representatives make any undertaking to update any such information subsequent to the date hereof. This presentation should not be construed as legal, tax, investment or other advice.

In addition, certain information and statements made in this presentation contain "forward-looking statements." Such forward-looking statements can be identified by the use of forward-looking terminology such as "anticipate", "estimate", "expect", "intend", "plan", "future" or "(f)". All forward looking statements are the Company's current expectation of future events and are subject to a number of factors that could cause actual results to differ materially from those described in the forward-looking statements. Caution should be taken with respect to such statements and you should not place undue reliance on any such forward-looking statements.


Certain industry and market data in this presentation was obtained from various trade associations, and the Company has not verified such data with independent sources. Accordingly, the Company makes no representations as to the accuracy or completeness of that data, and such data involves risks and uncertainties and is subject to change based on various factors. All the USD figures in this presentation are converted with exchange rate of 1,150 KRW / 1 USD.

This presentation does not constitute an offer or invitation to purchase or subscribe for any shares or other securities of the Company and neither any part of the materials nor any information or statement contained therein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Any decision to purchase shares in any offering of shares of the Company should be made solely on the basis of the information contained in the prospectus which may be published or distributed in due course in connection with any offering of shares of the Company, if any.

Contents



Company
Overview



Our Competitive
Edge



Potential
Outlooks



Financial
Highlights



Company Overview

- 1. Overview**
- 2. History**

Overview

Company Profile

Name	Bioneer Corporation
CEO	Han-Oh, Park
Established	Aug. 28, 1992
Capital	12.6 Billion KRW
Market Cap	2 Trillion KRW (as of Aug. 31, 2021)
Employees	546 (as of Jun. 30, 2021)
Business Sectors	MDx, Probiotics, RNAi Drugs
Located	Daejeon, South Korea
Webpage	www.bioneer.com

Chairman & CEO

"Making a Healthier
Future for Humanity with
Genomic Technology"




Han-Oh, PARK


- B.S. Chemistry, Seoul National University (1984)
- Ph.D. Biochemistry, KAIST (1992)
- Vice President, Korea Biotechnology Industry Organization
- Adjunct Professor, KAIST
- Committee Member, Presidential Advisory Council on Science & Technology

Overview


Subsidiaries




Shareholders



History







Our Competitive Edge

- 1. Business Model**
- 2. Pipeline Diversification**
- 3. In-house Manufacturing**
- 4. IP Portfolio**

Business Model



Pipeline Diversification



In-House Manufacturing

Internalized System leads to Higher Cost-Efficiency and Profit Margin



Internalization allows the highest gross profit margin amongst all Korean biotech companies.



- Design siRNA sequences in 2 days.
- Synthesize 1,000+ preliminary candidates in 1 week.
- Discover new drug candidates in 1 month with in-house developed instruments.



One-stop total solution for MDx warrants consistent quality and maintenance service.


IP Portfolio

“The bio industry is a patent-protected monopoly manufacturing industry”

Field	Domestic		Overseas	
	Applied	Registered	Applied	Registered
Oligo DNA/RNA Synthesis and Technology	1	3	2	4
Developing New Drugs	9	25	58	98
Functional Microorganisms	-	3	2	10
Diagnostic Kit	3	36	4	39
Genetic Analysis System	11	22	37	102
Nano Technology	4	21	18	38
Others	4	14	16	17
TOTAL 450 Registered, 184 Applied	30	129	154	321

Domestic Biotech Firms' Average No. of Patents: 84

(from Baillie Gifford's Pacific Horizon Investment Trust PLC)



Potential Outlooks

- 1. Next-generation PCR Devices**
- 2. Increasing Probiotics Sales**
- 3. SAMiRNA™ Platform**

Next-generation qPCR Devices

Ubiquitous & Precise Diagnosis is a Key to Prevent Pandemics



IRON-qPCR™

- Fully automated
- From nucleic extraction to results in ~30 minutes
- Simultaneously diagnose 40 pathogens of 2 people




ExiStation™ FA96

- Fully automated
- From decapping to results in ~100 minutes
- Simultaneously diagnose 20 pathogens of 6-94 people


Increasing Probiotics Sales

First Premium Weight-Loss Probiotics certified by KFDA

Expansion in Global Probiotics Market




Consistent Increase in Inflow




- **Market Diversification with Product Line Extension**
- **Sales Channel Expansion, both online and offline**
- **High Retention Rate proves Strong Customer Loyalty**
- **Patented in 10 countries, Registered Trademarks in 20+ countries**

SAMiRNA™ Platform


“Simple is the best”



PEG and Hydrocarbon synthesis to the ends of RNAi sequence






Self-assembly into a sphere



Enters target location through EPR effect

Comparison Matrix

SAMiRNA™ is an Unique Single-Molecular Nanoparticle siRNA

	Naked Oligo	SAMiRNA™	Lipid Nanoparticle
			
High Delivery Efficiency	✓	✓	✓
No Immune Response	✓	✓	✗
Low Manufacturing Cost	✗	✓	✗
Easy Quality Control	✗	✓	✗

Unmet Needs


SAMiRNA™ is the Next Generation siRNA Therapeutics

High Delivery Efficiency

No Immune Response

Low Manufacturing Cost

Easy Quality Control



SAMiRNA synthesis

SAMiRNA prep. in buffer

Freeze-drying



Financial Highlights

- 1. Balance Sheet**
- 2. Income Statement**
- 3. CAPEX Expansion**


Balance Sheet

[K-IFRS Consolidated]


[Unit: Million USD]

Account	2019	2020	2021.1H
Current Asset	37.4	82.7	126.9
(Cash & Cashable Asset)	5.2	29.3	33.8
Non-current Asset	34.0	83.6	97.5
(Tangible Asset)	27.7	72.2	84.5
TOTAL ASSETS	71.4	166.2	224.4
Current Liability	31.3	30.6	65.6
Non-current Liability	12.6	7.0	0.9
TOTAL LIABILITIES	43.9	37.6	66.5
Paid-in Capital	9.9	10.9	11.0
Capital Surplus	111.7	161.1	162.0
Retained Earnings	Δ 109.3	Δ 52.3	Δ 20.7
TOTAL EQUITY	27.5	128.7	157.9

Current Ratio




D/E Ratio



Net Cash

* Including short-term financial instruments

[Unit: Million USD]



Income Statement


[K-IFRS Consolidated]

[Unit: Million USD]

Account	FY 2020						FY 2021			
	1Q	2Q	1 st Half	3Q	4Q	Total	1Q	2Q	1 st Half	YoY
Sales Revenue	11.0	51.5	62.5	64.1	53.4	180.0	43.4	47.1	90.4	44.7%
Molecular Diagnostics	6.1	42.5	48.6	50.1	38.3	137.0	28.3	29.0	57.2	17.7%
Probiotics	4.9	9.0	13.9	14.0	15.1	43.0	15.1	18.1	33.2	139.3%
Gross Profit	6.5	41.2	47.7	51.8	41.8	141.4	32.6	37.3	69.9	46.4%
Operating Expenses	6.9	13.4	20.3	15.0	14.6	49.9	16.8	17.6	34.4	69.6%
Operating Profit	-0.4	27.9	27.5	36.8	27.2	91.5	15.8	19.7	35.5	29.2%
Molecular Diagnostics	-1.2	26.8	25.6	33.6	23.3	82.5	13.9	13.3	27.2	6.0%
Probiotics	0.8	1.0	1.8	3.2	3.8	8.9	1.9	6.4	8.3	351.6%
Non-operating Profit	-17.6	8.2	-9.4	-33.5	-0.1	-43.1	1.9	0.4	2.3	<i>Turn into +</i>
Profit Before Income Tax	-18.0	36.0	18.0	3.3	27.1	48.4	17.6	20.2	37.8	109.7%
Net Profit	-18.1	36.1	17.9	2.8	30.8	51.5	13.3	15.1	28.4	58.4%
<i>Gross Profit Margin (GPM)</i>	<i>59.5%</i>	<i>80.0%</i>	<i>76.3%</i>	<i>80.9%</i>	<i>78.3%</i>	<i>78.5%</i>	<i>75.2%</i>	79.2%	77.3%	+1.0%P
<i>Operating Profit Margin (OPM)</i>	<i>-%</i>	<i>54.1%</i>	<i>43.9%</i>	<i>57.5%</i>	<i>50.9%</i>	<i>50.8%</i>	<i>36.4%</i>	41.8%	39.2%	-4.7%P
<i>Net Profit Margin(NPM)</i>	<i>-%</i>	<i>69.9%</i>	<i>28.7%</i>	<i>4.3%</i>	<i>57.6%</i>	<i>28.6%</i>	<i>30.7%</i>	32.1%	31.4%	+2.7%P

CAPEX Expansion

Driving Force for Mid & Long-term Growth via CAPEX Investment




Thank You

IR Contact

E-mail : irteam@bioneer.co.kr



Phone: +82 2. 739. 6083



Appendix - Prospective Cash Cow

CosmeRNA ARI

SAMiRNA-AR inhibits Androgen Receptors in human DPCs and hair follicles



- **In process of Commercialization**
 - Domestic : Certification by KFDA in progress
 - European : Clinical Test by Dermatest (Germany) in progress
- **Expects to be the Game Changer**
 - Apply to scalp, once a week
 - Resolves side effects of *Propecia*
- **Supporting evidence for SAMiRNA's Nontoxicity**

Nano-Bio Business

Nano-Beads

- Main ingredients of the Genomic DNA Extraction Kit and Protein Purification Kit
- AccuBead™, AccuNanoBead™

Carbon NanoTubes (CNT)


- Development of CNT/ carbon Fiber Plane Heater
- Applicable in :
Scientific equipment, home appliances, electric vehicles, instantaneous heating products, and electronic components

Silver-coated Copper Nanowires

- Innovative shielding material, replacing the Silver Nanopowder
- Applicable in :
Lighting, display, memory semiconductor, battery, and antenna

Appendix - Sales Breakdown

By Business Division



By Region

